Jacobs Levy Equity Management
KYNB

Jacobs Levy Equity Management’s Kyntra Bio KYNB Stock Holding History

Jacobs Levy Equity Management’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-84,342
Closed -$842K – 975
2024
Q3 		$842K Buy
84,342
+146
+0.2% +$2.2K ﹤0.01% 756
2024
Q2 		$1.88M Sell
84,196
-4,108
-5% -$127K 0.01% 612
2024
Q1 		$5.19M Sell
88,304
-11,276
-11% -$486K 0.02% 422
2023
Q4 		$2.21M Sell
99,580
-2,705
-3% -$40.8K 0.01% 586
2023
Q3 		$2.21M Buy
102,285
+62,396
+156% +$2.45M 0.01% 545
2023
Q2 		$2.69M Sell
39,889
-4,876
-11% -$2.02M 0.02% 522
2023
Q1 		$20.9M Sell
44,765
-12,300
-22% -$6.51M 0.13% 180
2022
Q4 		$22.9M Sell
57,065
-156
-0.3% -$59.8K 0.15% 172
2022
Q3 		$18.6M Sell
57,221
-1,086
-2% -$350K 0.15% 178
2022
Q2 		$15.4M Sell
58,307
-365
-0.6% -$93.3K 0.12% 208
2022
Q1 		$17.6M Buy
58,672
+3,215
+6% +$1.12M 0.12% 203
2021
Q4 		$19.5M Buy
55,457
+15,466
+39% +$4.82M 0.13% 188
2021
Q3 		$10.2M Buy
39,991
+896
+2% +$317K 0.07% 294
2021
Q2 		$26M Buy
39,095
+37,416
+2,228% +$21.6M 0.18% 154
2021
Q1 		$1.46M Sell
1,679
-3,213
-66% -$3.42M 0.01% 654
2020
Q4 		$4.54M Sell
4,892
-2,833
-37% -$2.98M 0.04% 411
2020
Q3 		$7.94M Buy
+7,725
New +$8.31M 0.08% 255
2020
Q2 		– Sell
-4,640
Closed -$4.03M – 1071
2020
Q1 		$4.03M Sell
4,640
-3,153
-40% -$3.13M 0.05% 332
2019
Q4 		$8.36M Buy
7,793
+1,710
+28% +$1.75M 0.08% 279
2019
Q3 		$5.62M Buy
6,083
+752
+14% +$826K 0.07% 316
2019
Q2 		$6.02M Buy
+5,331
New +$5.83M 0.08% 307
2017
Q3 		– Sell
-3,533
Closed -$2.85M – 974
2017
Q2 		$2.85M Sell
3,533
-2,837
-45% -$1.98M 0.06% 353
2017
Q1 		$3.93M Sell
6,370
-1,827
-22% -$1.11M 0.08% 296
2016
Q4 		$4.39M Buy
8,197
+255
+3% +$127K 0.08% 273
2016
Q3 		$4.11M Buy
7,942
+1,232
+18% +$580K 0.07% 296
2016
Q2 		$2.75M Buy
6,710
+2,034
+43% +$931K 0.06% 362
2016
Q1 		$2.49M Buy
+4,676
New +$2.33M 0.05% 360

Other funds holding KYNB

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Jacobs Levy Equity Management's KYNB Position: Q4 2024 in Review

Jacobs Levy Equity Management sold out of Kyntra Bio (KYNB) in Q4 2024, closing a stake of 84,342 shares — an estimated $842K sold.

Jacobs Levy Equity Management first reported a position in KYNB in Q1 2016 and held it in 27 quarters. The position peaked at $26M in Q2 2021. 68 funds tracked by Wall St. Rank hold KYNB as of Q4 2024.

  • Jacobs Levy Equity Management reported no remaining Kyntra Bio position as of Q4 2024 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 84,342 Kyntra Bio shares in Q4 2024, an estimated $842K.
  • Jacobs Levy Equity Management first reported a position in Kyntra Bio in Q1 2016 and held it in 27 quarters.
  • Jacobs Levy Equity Management's Kyntra Bio position peaked at $26M in Q2 2021.
  • 68 funds tracked by Wall St. Rank held Kyntra Bio as of Q4 2024.

Based on Jacobs Levy Equity Management's 13F filing for Q4 2024, filed 14 Feb 2025.